Pathophysiology of dyspnea in COPD

References

• O’Donnell DE, Banzett RB, Carrieri-Kohlman V, et al. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc. 2007;4:145–168.
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2017. Available from: http://www.goldcopd.org
   Google Scholar
• Inspiratory dyspnea. Mosby’s Medical Dictionary. 8th ed. n.d. 2009 Available from: http://medical-dictionary.thefreedictionary.com/inspiratory+dyspnea
   Google Scholar
• Expiratory dyspnea. n.d. Farlex Partner Medical Dictionary, 2012. Available from: http://medical-dictionary.thefreedictionary.com/expiratory+dyspnea
   Google Scholar
• Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185:435–452.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, de la Roza C, Morera J, et al. Chronic respiratory symptoms, spirometry and knowledge of COPD among general population. Respir Med. 2006;100:1973–1980.
   PubMed Web of Science ®Google Scholar
• Gronseth R, Vollmer WM, Hardie JA, et al. Predictors of dyspnoea prevalence: results from the BOLD study. Eur Respir J. 2014;43:1610–1620.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Murio C, Tirado-Conde G, et al. Geographic differences in clinical characteristics and management of COPD: the EPOCA study. Int J Chron Obstruct Pulmon Dis. 2008;3:803–814.
   PubMedGoogle Scholar
• Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121:1434–1440.
   PubMed Web of Science ®Google Scholar
• Neuman A, Gunnbjörnsdottir M, Tunsäter A, et al. Dyspnea in relation to symptoms of anxiety and depression: a prospective population study. Respir Med. 2006;100:1843–1849.
   PubMed Web of Science ®Google Scholar
• Bailey PH. The dyspnea-anxiety-dyspnea cycle – COPD patients’ stories of breathlessness: it’s scary when you can’t breathe. Qual Health Res. 2004;14:760–778.
   PubMed Web of Science ®Google Scholar
• Marciniuk DD, Goodridge D, Hernandez P, et al. Canadian Thoracic Society COPD clinical assembly alpha-1 antitrypsin deficiency expert working group. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011;18:69–78.
   PubMed Web of Science ®Google Scholar
• Watson L, Vestbo J, Postma DS, et al. Gender differences in the management and experience of chronic obstructive pulmonary disease. Respir Med. 2004;98:1207–1213.
   PubMed Web of Science ®Google Scholar
• Naberan K, Azpeitia Á, Cantoni J, et al. Impairment of quality of life in women with chronic obstructive pulmonary disease. Respir Med. 2012;106:367–373.
   PubMed Web of Science ®Google Scholar
• Evans KC, Banzett RB, Adams L, et al. BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. J Neurophysiol. 2002;88:1500–1511.
   PubMed Web of Science ®Google Scholar
• Mahler DA, O’Donnell DE. Recent advances in dyspnea. Chest. 2015;147:232–241.
   PubMed Web of Science ®Google Scholar
• Lansing RW, Gracely RH, Banzett RB. The multiple dimensions of dyspnea: review and hypotheses. Respir Physiol Neurobiol. 2009;167:53–60.
   PubMed Web of Science ®Google Scholar
• Binks AP, Moosavi SH, Banzett RB, et al. “Tightness” sensation of asthma does not arise from the work of breathing. Am J Respir Crit Care Med. 2002;165:78–82.
   PubMed Web of Science ®Google Scholar
• Stanford School of Medicine. Dyspnea mechanisms flowchart. [cited 2017 Jan 28]. Available from: https://palliative.stanford.edu/dyspnea-how-to-assess-and-palliate-dyspnea-air-hunger/causes-flowchart/
   Google Scholar
• Pecchiari M, Radovanovic D, Santus P, et al. Airway occlusion assessed by single breath N(2) test and lung P-V curve in healthy subjects and COPD patients. Respir Physiol Neurobiol. 2016;234:60–68.
   PubMed Web of Science ®Google Scholar
• Rabe KF. Improving dyspnea in chronic obstructive pulmonary disease: optimal treatment strategies. Proc Am Thorac Soc. 2006;3:270–275.
   PubMedGoogle Scholar
• Ferguson GT. Why does the lung hyperinflate? Proc Am Thorac Soc. 2006;3:176–179.
   PubMedGoogle Scholar
• O’Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3:180–184.
   PubMedGoogle Scholar
• Perez T, Burgel PR, Paillasseur JL, et al. Modified Medical Research Council scale vs. baseline dyspnea index to evaluate dyspnea in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1663–1672.
   PubMed Web of Science ®Google Scholar
• Redelmeier DA, Goldstein RS, Min ST, et al. Spirometry and dyspnea in patients with COPD: when small differences mean little. Chest. 1996;109:1163–1168.
   PubMed Web of Science ®Google Scholar
• Westwood M, Bourbeau J, Jones PW, et al. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011;12:40.
   PubMed Web of Science ®Google Scholar
• Mota S, Casan P, Drobnic F, et al. Expiratory flow limitation during exercise in competition cyclists. J Appl Physiol. 1999;86:611–616.
   PubMed Web of Science ®Google Scholar
• Rossi A, Aisanov Z, Avdeev S, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med. 2015;109:785–802.
   PubMed Web of Science ®Google Scholar
• Garcia-Rio F, Lores V, Mediano O, et al. Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med. 2009;180:506–512.
   PubMed Web of Science ®Google Scholar
• Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:591–597.
   PubMed Web of Science ®Google Scholar
• Shin TR, Oh YM, Park JH, et al. The prognostic value of residual volume/total lung capacity in patients with chronic obstructive pulmonary disease. J Korean Med Sci. 2015;30:1459–1465.
   PubMed Web of Science ®Google Scholar
• Casaburi R, Rennard SI. Exercise limitation in chronic obstructive pulmonary disease: the O’Donnell threshold. Am J Respir Crit Care Med. 2015;191:873–875.
   PubMed Web of Science ®Google Scholar
• Lahaije AJ, van Helvoort HA, Dekhuijzen PN, et al. Resting and ADL-induced dynamic hyperinflation explain physical inactivity in COPD better than FEV1. Respir Med. 2013;107:834–840.
   PubMed Web of Science ®Google Scholar
• Kitaguchi Y, Fujimoto K, Hanaoka M, et al. Pulmonary function impairment in patients with combined pulmonary fibrosis and emphysema with and without airflow obstruction. Int J Chron Obstruct Pulmon Dis. 2014;9:805–811.
   PubMed Web of Science ®Google Scholar
• Chin RC, Guenette JA, Cheng S, et al. Does the respiratory system limit exercise in mild chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2013;187:1315–1323.
   PubMed Web of Science ®Google Scholar
• Santus P, Radovanovic D, Henchi S, et al. Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients. Respir Physiol Neurobiol. 2014;197:36–45.
   PubMed Web of Science ®Google Scholar
• van der Molen T, Miravitlles M, Kocks JW. COPD management: role of symptom assessment in routine clinical practice. Int J Chron Obstruct Pulmon Dis. 2013;8:461–471.
   PubMed Web of Science ®Google Scholar
• Crisafulli E, Clini EM. Measures of dyspnea in pulmonary rehabilitation. Multidiscip Respir Med. 2010;5:202–210.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Ward J, Waterman LA, et al. Patient-reported dyspnea in COPD reliability and association with stage of disease. Chest. 2009;136:1473–1479.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Dyspnea. Am J Respir Crit Care Med. 1999;159:321–340.
   PubMed Web of Science ®Google Scholar
• Fierro-Carrion G, Mahler DA, Ward J, et al. Comparison of continuous and discrete measurements of dyspnea during exercise in patients with COPD and normal subjects. Chest. 2004;125:77–84.
   PubMed Web of Science ®Google Scholar
• von Leupoldt A, Balewski S, Petersen S, et al. Verbal descriptors of dyspnea in patients with COPD at different intensity levels of dyspnea. Chest. 2007;132:141–147.
   PubMed Web of Science ®Google Scholar
• Ofir D, Laveneziana P, Webb KA, et al. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:622–629.
   PubMed Web of Science ®Google Scholar
• Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140:331–342.
   PubMed Web of Science ®Google Scholar
• D’Angelo E, Santus P, Civitillo MF, et al. Expiratory flow-limitation and heliox breathing in resting and exercising COPD patients. Respir Physiol Neurobiol. 2009;169:291–296.
   PubMed Web of Science ®Google Scholar
• Diaz O, Villafranca C, Ghezzo H, et al. Breathing pattern and gas exchange at peak exercise in COPD patients with and without tidal flow limitation at rest. Eur Respir J. 2001;17:1120–1127.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Rebuck AS. Inspiratory and expiratory resistive loading as a model of dyspnea in asthma. Respiration. 1983;44:425–432.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Worth H, Soler Cataluña JJ, et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res. 2014;15:122.
   PubMed Web of Science ®Google Scholar
• Roche N, Chavannes NH, Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respir Res. 2013;14:112.
   PubMed Web of Science ®Google Scholar
• Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37:264–272.
   PubMed Web of Science ®Google Scholar
• Lange P, Marott JL, Vestbo J, et al. Prevalence of night-time dyspnoea in COPD and its implications for prognosis. Eur Respir J. 2014;43:1590–1598.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care. 2003;48:1204–1213; discussion 1213–1215.
   PubMedGoogle Scholar
• Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1608–1613.
   PubMed Web of Science ®Google Scholar
• Anzueto A, Calverley PMA, Wise RA, et al. Assessing COPD profiles and outcomes by dyspnoea severity. Eur Respir J. 2016;48(suppl60):PA4057 DOI:10.1183/13993003.congress-2016
   Web of Science ®Google Scholar
• Miravitlles M. Cough and sputum production as risk factors for poor outcomes in patients with COPD. Respir Med. 2011;105:1118–1128.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish Society of Pulmonology and Thoracic Surgery. Spanish COPD guidelines (GesEPOC): pharmacological treatment of stable COPD. Arch Bronconeumol. 2012;48:247–257.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soriano JB, Ancochea J, et al. Characterisation of the overlap COPD–asthma phenotype: focus on physical activity and health status. Respir Med. 2013;107:1053–1060.
   PubMed Web of Science ®Google Scholar
• Papaiwannou A, Zarogoulidis P, Porpodis K, et al. Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): current literature review. J Thorac Dis. 2014;6(suppl 1):S146–S151.
   PubMed Web of Science ®Google Scholar
• Scioscia G, Blanco I, Arismendi E, et al. Different dyspnoea perception in COPD patients with frequent and infrequent exacerbations. Thorax. 2017;72:117–121.
   PubMed Web of Science ®Google Scholar
• Meek PM, Banzett R, Parshall MB, et al. Reliability and validity of the multidimensional dyspnea profile. Chest. 2012;141:1546–1553.
   PubMed Web of Science ®Google Scholar
• Banzett RB, Pedersen SH, Schwartzstein RM, et al. The affective dimension of laboratory dyspnea: air hunger is more unpleasant than work/effort. Am J Respir Crit Care Med. 2008;177:1384–1390.
   PubMed Web of Science ®Google Scholar
• Cortopassi F, Castro AA, Porto EF, et al. Comprehensive exercise training improves ventilatory muscle function and reduces dyspnea perception in patients with COPD. Monaldi Arch Chest Dis. 2009;71:106–112.
   PubMedGoogle Scholar
• Wheaton AG, Ford ES, Thompson WW, et al. Pulmonary function, chronic respiratory symptoms, and health-related quality of life among adults in the United States – National Health and Nutrition Examination Survey 2007–2010. BMC Public Health. 2013;13:854.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Ferrer J, Baro E, et al. Differences between physician and patient in the perception of symptoms and their severity in COPD. Respir Med. 2013;107:1977–1985.
   PubMed Web of Science ®Google Scholar
• Yorke J, Moosavi SH, Shuldham C, et al. Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax. 2010;65:21–26.
   PubMed Web of Science ®Google Scholar
• Banzett RB, O’Donnell CR, Guilfoyle TE, et al. Multidimensional dyspnea profile: an instrument for clinical and laboratory research. Eur Respir J. 2015;45:1681–1691.
   PubMed Web of Science ®Google Scholar
• Hayen A, Herigstad M, Pattinson KT. Understanding dyspnea as a complex individual experience. Maturitas. 2013;76:45–50.
   PubMed Web of Science ®Google Scholar
• Camillo CA, Pitta F, Possani HV, et al. Heart rate variability and disease characteristics in patients with COPD. Lung. 2008;186:393–401.
   PubMed Web of Science ®Google Scholar
• Janssens T, De Peuter S, Stans L, et al. Dyspnea perception in COPD: association between anxiety, dyspnea-related fear, and dyspnea in a pulmonary rehabilitation program. Chest. 2011;140:618–625.
   PubMed Web of Science ®Google Scholar
• De Peuter S, Janssens T, Van Diest I, et al. Dyspnea-related anxiety: the Dutch version of the breathlessness beliefs questionnaire. Chron Respir Dis. 2011;8:11–19.
   PubMed Web of Science ®Google Scholar
• Herigstad M, Hayen A, Evans E, et al. Dyspnea-related cues engage the prefrontal cortex: evidence from functional brain imaging in COPD. Chest. 2015;148:953–961.
   PubMed Web of Science ®Google Scholar
• Herigstad M, Hayen A, Reinecke A, et al. Development of a dyspnoea word cue set for studies of emotional processing in COPD. Respir Physiol Neurobiol. 2016;223:37–42.
   PubMed Web of Science ®Google Scholar
• Yorke J, Swigris J, Russell AM, et al. Dyspnea-12 is a valid and reliable measure of breathlessness in patients with interstitial lung disease. Chest. 2011;139:159–164.
   PubMed Web of Science ®Google Scholar
• Casaburi R, Maltais F, Porszasz J, et al. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11:1351–1361.
   PubMedGoogle Scholar
• O’Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832–840.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Sciurba F, Celli B, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest. 2006;130:647–656.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Singh D, Di Scala L, et al. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012;7:503–513.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Wagner F, Khindri S, et al. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD. 2011;8:340–345.
   PubMedGoogle Scholar
• Neder JA, Fuld JP, Overend T, et al. Effects of formoterol on exercise tolerance in severely disabled patients with COPD. Respir Med. 2007;101:2056–2064.
   PubMed Web of Science ®Google Scholar
• Beier J, Kirsten A, Mróz R, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. Copd. 2013;10:511–522.
   PubMedGoogle Scholar
• Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37:273–279.
   PubMed Web of Science ®Google Scholar
• Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65:473–479.
   PubMed Web of Science ®Google Scholar
• Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J. 2002;19:936–943.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilatory therapy: the SHINE study. Eur Respir J. 2013;42:1484–1494.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22:912–919.
   PubMed Web of Science ®Google Scholar
• Han J, Dai L, Zhong N. Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Pulm Med. 2013;13:26.
   PubMed Web of Science ®Google Scholar
• Geake JB, Dabscheck EJ, Wood-Baker R, et al. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;1:CD010139.
   PubMedGoogle Scholar
• O’Donnell DE, Casaburi R, Vincken W, et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med. 2011;105(7):1030–1036.
   PubMed Web of Science ®Google Scholar
• Santus P, Radovanovic D, Di Marco F, et al. Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study. Pulm Pharmacol Ther. 2015;35:42–49.
   PubMed Web of Science ®Google Scholar
• Santus P, Centanni S, Verga M, et al. Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation. Respir Med. 2006;100:1277–1281.
   PubMed Web of Science ®Google Scholar
• Derom E, Brusselle GG, Joos GF. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:3163–3177.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Decramer M, D’Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J. 2014;43(6):1599–1609.
   PubMed Web of Science ®Google Scholar
• Morgan WC, Hodge HL. Diagnostic evaluation of dyspnea. Am Fam Physician. 1998;57:711–716.
   PubMed Web of Science ®Google Scholar
• Yilmaz Yelvar GD, Çirak Y, Demir YP, et al. Immediate effect of manual therapy on respiratory functions and inspiratory muscle strength in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:1353–1357.
   PubMed Web of Science ®Google Scholar
• Green RH, Singh SJ, Williams J, et al. A randomized controlled trial of four weeks versus seven weeks of pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax. 2001;56:143–145.
   PubMed Web of Science ®Google Scholar
• Schwartzstein RM, Lahive K, Pope A, et al. Cold facial stimulation reduces breathlessness induced in normal subjects. Am Rev Respir Dis. 1987;136:58–61.
   PubMed Web of Science ®Google Scholar
• Crisafulli E, Costi S, De Blasio F, et al. Effects of a walking aid in COPD patients receiving oxygen therapy. Chest. 2007;131:1068–1074.
   PubMed Web of Science ®Google Scholar
• Von Leupoldt A, Taube K, Lehmann K, et al. The impact of anxiety and depression on outcomes of pulmonary rehabilitation in patients with COPD. Chest. 2011;140:730–736.
   PubMed Web of Science ®Google Scholar
• Keil DC, Stenzel NM, Kühl K, et al. The impact of chronic obstructive pulmonary disease-related fears on disease-specific disability. Chron Respir Dis. 2014;11:31–40.
   PubMed Web of Science ®Google Scholar